Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer-Reference-Cited by-同舟云学术

Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer

Published:2012-07-05 Issue:2 Volume:31 Page:253-259
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Schnoeller Thomas,Jentzmik Florian,Rinnab Ludwig,Cronauer Marcus V.,Damjanoski Ilija,Zengerling Friedemann,Ghazal Andreas Al,Schrader Mark,Schrader Andres J.

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/content/pdf/10.1007/s00345-012-0902-5.pdf

Reference21 articles.

1. Morgentaler A, Traish AM (2009) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55:310–320

2. Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK (2009) Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology 73:356–361

3. Solania A, Gallina A, Briganti A, Abdollah F, Suardi N, Capitanio U, Colombo R, Freschi M, Rigatti P, Montorsi F (2011) Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer 117:3953–3962

4. Ribeiro M, Ruff P, Falkson G (1997) Low serum testosterone and a younger age predict for poor outcome in metastatic prostate cancer. Am J Clin Oncol 20:605–608

5. Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, Marberger M (2001) High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47:52–58

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Periprostatic adipose tissue inhibits tumor progression by secreting apoptotic factors: A natural barrier induced by the immune response during the early stages of prostate cancer;Oncology Letters;2024-08-08

2. Anti-Müllerian hormone: a novel biomarker for aggressive prostate cancer? Emerging evidence from a prospective study of radical prostatectomies;Hormones;2023-12-21

3. Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts;British Journal of Cancer;2023-12-12

4. Anti-Müllerian Hormone: a novel biomarker for aggressive prostate cancer? Emerging evidence from a prospective study of radical prostatectomies;2023-06-14

5. Impacto de la distribución del tejido adiposo en la recidiva del cáncer de próstata tras la prostatectomía radical;Actas Urológicas Españolas;2023-03